- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04697784
Estudio posterior a la aprobación del sistema de injerto de stent abdominal TREO (TREO PAS)
Estudio posterior a la aprobación del sistema de injerto de stent abdominal TREO (P190015) en pacientes con aneurismas aórticos abdominales infrarrenales y aortoilíacos
The purpose of this study is to determine the long-term performance of the TREO Abdominal Stent-Graft as a treatment for patients with Infrarenal Abdominal Aortic Aneurysms or Aorto-iliac Aneurysms.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a prospective, multi-center, non-randomized, single-arm, post-market, non-interventional study of treatment with the TREO Abdominal Stent-Graft in subjects with Infrarenal Abdominal Aortic Aneurysms or Aorto-iliac Aneurysms. The study will include a minimum of 300 subjects treated with the TREO Abdominal Stent-Graft at up to 55 investigational sites in the US.
The primary objective is the collection of real world safety and effectiveness outcomes of the TREO Abdominal Stent-Graft System in an all-comers population eligible for the endovascular treatment of AAA in routine clinical practice, with emphasis on subjects that experience a device stent-strut or barb fracture.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85006
- Vascular Surgery Specialists
-
Tucson, Arizona, Estados Unidos, 85718
- Pima Heart and Vascular
-
-
California
-
Fresno, California, Estados Unidos, 93701
- University of California, San Francisco-Fresno
-
La Jolla, California, Estados Unidos, 92037
- University of California, San Diego
-
San Diego, California, Estados Unidos, 92161
- VA San Diego
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- University of Colorado Anschutz
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06520
- Yale University
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20010
- Medstar Washington Hospital Center
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32610
- University of Florida
-
Gainesville, Florida, Estados Unidos, 32608
- Malcom Randall VA Medical Center
-
Pensacola, Florida, Estados Unidos, 32504
- Coastal Vascular and Interventional
-
Tampa, Florida, Estados Unidos, 33606
- University of South Florida / Tampa General Hospital
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30342
- Northside Hospital
-
Atlanta, Georgia, Estados Unidos, 30309
- Piedmont Heart Institute
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- University of Iowa Hospital and Clinic
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Estados Unidos, 02111
- Tufts Medical Center
-
-
Michigan
-
Bay City, Michigan, Estados Unidos, 48708
- McLaren Bay Region
-
Detroit, Michigan, Estados Unidos, 48202
- Henry Ford Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55407
- Minneapolis Heart Institute Foundation
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Barnes Jewish Hospital at Washington University
-
-
New Jersey
-
Hackensack, New Jersey, Estados Unidos, 07601
- Hackensack University Medical Center
-
New Brunswick, New Jersey, Estados Unidos, 08901
- Rutgers Robert Wood Johnson Medical Center
-
-
New York
-
New York, New York, Estados Unidos, 10075
- Lenox Hill Hospital / Northwell Health
-
Stony Brook, New York, Estados Unidos, 11794-8191
- Stony Brook Medical Center
-
Syracuse, New York, Estados Unidos, 13210
- SUNY Upstate Medical University
-
The Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center
-
-
North Carolina
-
Asheville, North Carolina, Estados Unidos, 27607
- Mission Health
-
Greenville, North Carolina, Estados Unidos, 27834
- East Carolina University
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Oregon Health and Science University
-
Portland, Oregon, Estados Unidos, 97239
- VA Portland Healthcare System
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19140
- Temple University Hospital
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- University of Pittsburgh Medical Center
-
-
Tennessee
-
Kingsport, Tennessee, Estados Unidos, 37660
- Wellmont Cardiology Services
-
-
Texas
-
Austin, Texas, Estados Unidos, 78756
- St. David's Healthcare (Cardiothoracic and Vascular Surgeons)
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84132
- University of Utah Hospital
-
-
Virginia
-
Norfolk, Virginia, Estados Unidos, 22042
- Sentara Heart Hospital
-
Richmond, Virginia, Estados Unidos, 23282
- Virginia Commonwealth University
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Medical College of Wisconsin
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Willing and able to comply with all study procedures and visits.
- Written informed consent to participate in the study.
- Patient's aneurysm can be treated with the TREO Abdominal Stent-Graft System.
- Adequate data (medical records/imaging studies) available to analyze the primary endpoints for patients enrolled retrospectively.
Exclusion Criteria:
• Medical, social or psychological problems that, in the opinion of the investigator, preclude patient from receiving treatment with the TREO Abdominal Stent-Graft System.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Subjects who receive the TREO Abdominal Stent-Graft System
Eligible subjects will be implanted with the TREO Abdominal Stent-Graft System. |
The TREO Abdominal Stent-Graft System is intended for the treatment of infrarenal abdominal aortic aneurysms with or without iliac involvement. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of stent-strut fracture or barb separation as confirmed by the Imaging Core Laboratory.
Periodo de tiempo: Through 5 Years post-procedure
|
Incidence of fracture in a stent-strut or separation of one or more proximal fixation barbs as confirmed by the Imaging Core Laboratory upon review of post-implant imaging studies. |
Through 5 Years post-procedure
|
|
Incidence of secondary intervention for adverse events related to or caused as a result of stent-strut fracture or barb separation.
Periodo de tiempo: Through 5 Years post-procedure
|
Incidence of secondary intervention for adverse events related to or caused as a result of a fracture in a stent-strut or separation of one or more proximal fixation barbs. Relatedness to the device will be confirmed by the Clinical Events Committee (CEC) through review of available treatment and procedure records and reports of imaging studies. |
Through 5 Years post-procedure
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of participants with technical success at the conclusion of the index procedure
Periodo de tiempo: Through 5 Years post-procedure
|
Defined as the following:
|
Through 5 Years post-procedure
|
|
Major Adverse Events
Periodo de tiempo: Through 5 Years post-procedure
|
Incidence of the following Major Adverse Events
|
Through 5 Years post-procedure
|
|
Incidence of procedure-related clinical utility measures
Periodo de tiempo: Through 5 Years post-procedure
|
Reporting of procedural data collected during implant of the TREO Abdominal Stent-Graft System including: Procedure time (minutes), Fluoroscopy time (minutes), Contrast volume (mL), Access method (i.e. percutaneous, surgical cut down), Length of ICU stay (hours), Length of hospital stay post-procedure (days), Anesthesia Type. |
Through 5 Years post-procedure
|
|
Incidence of procedure-related complications
Periodo de tiempo: Through 5 Years post-procedure
|
Incidence of adverse events occurring during or following the implant determined by the CEC to be procedure-related. |
Through 5 Years post-procedure
|
|
Incidence of successful aneurysm treatment
Periodo de tiempo: 12 months post-implant
|
Successful aneurysm treatment is defined as:
|
12 months post-implant
|
|
Incidence of all-cause mortality
Periodo de tiempo: Through 5 Years post-procedure
|
Rate of mortality attributed to any causality as confirmed by the CEC. |
Through 5 Years post-procedure
|
|
Incidence of aneurysm-related mortality
Periodo de tiempo: Through 5 Years post-procedure
|
Rate of mortality attributed to the following causes as confirmed by the CEC: death due to a rupture, death within 30 days or prior to hospital discharge from primary procedure, or death within 30 days or prior to hospital discharge for a secondary procedure designed to treat the original aneurysm. |
Through 5 Years post-procedure
|
|
Incidence of aneurysm rupture
Periodo de tiempo: Through 5 Years post-procedure
|
Incidence of rupture of the native aneurysm sac post-implantation of the endograft as confirmed by the CEC. |
Through 5 Years post-procedure
|
|
Incidence of secondary interventions.
Periodo de tiempo: Through 5 Years post-procedure
|
Incidence of secondary procedures designed to treat or repair the original aneurysm treated with the TREO Abdominal Stent-Graft System |
Through 5 Years post-procedure
|
|
Incidence of conversion to open surgical repair.
Periodo de tiempo: Through 5 Years post-procedure
|
Incidence of conversion to open surgical AAA repair during the initial EVAR procedure secondary to any procedure-related complications as determined by the CEC. |
Through 5 Years post-procedure
|
|
Incidence of stent-graft occlusion (i.e., loss of patency)
Periodo de tiempo: Through 5 Years post-procedure
|
Incidence of stent-graft occlusion defined as the unintentional obstruction of the vascular/endograft lumen with minor obstruction (0-25%), minimal obstruction (26-74%), moderate obstruction (75-99%) or occlusion (100%) as confirmed by the Imaging Core Lab due to causes such as twisting or kinking of the prosthesis, oversizing and fabric pleating, or failure of the implant to fully open, or to mural thrombus deposition. |
Through 5 Years post-procedure
|
|
Incidence of device stenosis or kink
Periodo de tiempo: Through 5 Years post-procedure
|
Incidence of stenosis or kinking of the TREO Stent-Graft as confirmed by the Imaging Core Lab. |
Through 5 Years post-procedure
|
|
Incidence of loss of device integrity
Periodo de tiempo: Through 5 Years post-procedure
|
Incidence of changes in the structural integrity in a material component of the stent-graft such as a stent-strut fracture or separation of the proximal fixation barbs as confirmed by the Imaging Core Lab. |
Through 5 Years post-procedure
|
|
Incidence of aneurysm enlargement (>5mm as compared to 30-day imaging).
Periodo de tiempo: Through 5 Years post-procedure
|
Incidence of the increase in the aneurysm sac diameter > 5 mm at post-implant follow-up visits relative to the diameter determined at the first post-procedural imaging study, as confirmed by the Imaging Core Lab. |
Through 5 Years post-procedure
|
|
Incidence of stent-graft migration (>10mm as compared to 30-day imaging)
Periodo de tiempo: Through 5 Years post-procedure
|
Incidence of the longitudinal movement of all or part of a stent or attachment system for a distance of >10 mm relative to anatomical landmarks that were determined at the first post-procedural imaging study as confirmed by the Imaging Core Lab. |
Through 5 Years post-procedure
|
|
Incidence of Type I, II, III, IV or V Endoleaks
Periodo de tiempo: Through 5 Years post-procedure
|
Incidence of Type I, II, III, IV or V Endoleaks defined as the persistence of blood flow outside the lumen of the stent-graft but within the native aorta or adjacent vascular segment being treated by the stent-graft as determined by the Imaging Core Lab. |
Through 5 Years post-procedure
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Gretchen Wild, Terumo Aortic
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- IP-0021-20
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .